[8-K] The Oncology Institute, Inc. Warrant Reports Material Event
The Oncology Institute, Inc. furnished a press release that discloses its financial results and additional financial information for the three months ended June 30, 2025. The filing states the press release is provided as Exhibit 99.1 and clarifies that the information is being furnished rather than filed under the Exchange Act, limiting certain legal liabilities. The report lists the company’s registered securities (common stock: TOI; redeemable warrants: TOIIW) on Nasdaq and identifies the company as an emerging growth company. No detailed financial tables or specific line-item results are included in the 8-K text itself; readers must refer to Exhibit 99.1 for the full figures.
The Oncology Institute, Inc. ha reso pubblico un comunicato stampa che illustra i risultati finanziari e ulteriori informazioni finanziarie relativi ai tre mesi conclusisi il 30 giugno 2025. Nel documento si indica che il comunicato è fornito come Exhibit 99.1 e si precisa che le informazioni sono fornite e non depositate ai sensi dell'Exchange Act, limitando così alcune responsabilità legali. Il rapporto elenca i titoli registrati della società (azioni ordinarie: TOI; warrant rimborsabili: TOIIW) sul Nasdaq e identifica l'azienda come emerging growth company. Nel testo dell'8-K non sono incluse tabelle finanziarie dettagliate né risultati per voci di bilancio specifiche; per i dati completi è necessario consultare l'Exhibit 99.1.
The Oncology Institute, Inc. difundió un comunicado de prensa que revela sus resultados financieros y otra información financiera correspondientes a los tres meses terminados el 30 de junio de 2025. La presentación indica que el comunicado se proporciona como Exhibit 99.1 y aclara que la información se ha suministrado en lugar de presentarse conforme al Exchange Act, lo que limita ciertas responsabilidades legales. El informe enumera los valores registrados de la compañía (acciones comunes: TOI; warrants rescatables: TOIIW) en Nasdaq e identifica a la empresa como una emerging growth company. El texto del 8-K no incluye tablas financieras detalladas ni resultados por partidas; para las cifras completas debe consultarse el Exhibit 99.1.
The Oncology Institute, Inc.는 2025년 6월 30일로 종료된 3개월에 대한 재무 실적 및 추가 재무 정보를 공개하는 보도자료를 제공했습니다. 제출 문서는 해당 보도자료가 Exhibit 99.1로 제공되었음을 명시하며, 이 정보가 Exchange Act에 따라 filed가 아닌 furnished로 제공되어 특정 법적 책임이 제한됨을 분명히 합니다. 보고서에는 나스닥에 등록된 회사의 증권(보통주: TOI; 환매 가능한 워런트: TOIIW)이 기재되어 있고, 회사를 emerging growth company로 규정하고 있습니다. 8-K 본문에는 상세한 재무표나 항목별 구체적 결과가 포함되어 있지 않으므로 전체 수치는 Exhibit 99.1을 참고해야 합니다.
The Oncology Institute, Inc. a publié un communiqué de presse qui dévoile ses résultats financiers et des informations financières supplémentaires pour les trois mois clos le 30 juin 2025. Le dépôt indique que le communiqué est fourni en tant qu'Exhibit 99.1 et précise que les informations sont furnished et non filed au titre de l'Exchange Act, limitant certaines responsabilités juridiques. Le rapport énumère les titres enregistrés de la société (actions ordinaires : TOI ; warrants remboursables : TOIIW) cotés au Nasdaq et identifie la société comme une emerging growth company. Le texte de l'8-K ne contient pas de tableaux financiers détaillés ni de résultats par poste ; pour les chiffres complets, il faut se référer à l'Exhibit 99.1.
The Oncology Institute, Inc. hat eine Pressemitteilung herausgegeben, die die Finanzergebnisse und ergänzende Finanzinformationen für die drei Monate zum 30. Juni 2025 offenlegt. Die Einreichung weist darauf hin, dass die Pressemitteilung als Exhibit 99.1 beigefügt ist und stellt klar, dass die Informationen im Sinne des Exchange Act furnished und nicht filed wurden, wodurch bestimmte rechtliche Haftungen eingeschränkt sind. Der Bericht listet die registrierten Wertpapiere des Unternehmens (Stammaktien: TOI; rückzahlbare Warrants: TOIIW) an der Nasdaq auf und kennzeichnet das Unternehmen als emerging growth company. Im 8-K-Text sind keine detaillierten Finanztabellen oder spezifischen Postenaufstellungen enthalten; die vollständigen Zahlen sind in Exhibit 99.1 nachzulesen.
- Press release furnished as Exhibit 99.1 announcing financial results for the three months ended June 30, 2025
- Disclosure clarity: the company states the information is furnished and not filed, clarifying legal treatment
- Registered securities listed (TOI common stock and TOIIW warrants) and exchange (Nasdaq) are specified
- None.
Insights
TL;DR: Routine earnings disclosure furnished via press release; no new material amendment in the 8-K text itself.
The filing serves primarily to distribute the company’s quarter-end results to investors by furnishing a press release as Exhibit 99.1. Because the 8-K explicitly states the information is furnished and not filed, it limits Section 18 liabilities while still providing market access to quarter-end performance. The 8-K text does not include numerical results or commentary on drivers, so material assessment requires review of Exhibit 99.1.
TL;DR: Standard disclosure practice observed; governance and disclosure formality maintained.
The report follows customary disclosure procedure by furnishing an earnings press release and identifying exhibits. The document confirms registered securities and emerging growth company status which affects disclosure flexibility. There are no governance actions, executive changes, or material transactions disclosed within the 8-K text itself.
The Oncology Institute, Inc. ha reso pubblico un comunicato stampa che illustra i risultati finanziari e ulteriori informazioni finanziarie relativi ai tre mesi conclusisi il 30 giugno 2025. Nel documento si indica che il comunicato è fornito come Exhibit 99.1 e si precisa che le informazioni sono fornite e non depositate ai sensi dell'Exchange Act, limitando così alcune responsabilità legali. Il rapporto elenca i titoli registrati della società (azioni ordinarie: TOI; warrant rimborsabili: TOIIW) sul Nasdaq e identifica l'azienda come emerging growth company. Nel testo dell'8-K non sono incluse tabelle finanziarie dettagliate né risultati per voci di bilancio specifiche; per i dati completi è necessario consultare l'Exhibit 99.1.
The Oncology Institute, Inc. difundió un comunicado de prensa que revela sus resultados financieros y otra información financiera correspondientes a los tres meses terminados el 30 de junio de 2025. La presentación indica que el comunicado se proporciona como Exhibit 99.1 y aclara que la información se ha suministrado en lugar de presentarse conforme al Exchange Act, lo que limita ciertas responsabilidades legales. El informe enumera los valores registrados de la compañía (acciones comunes: TOI; warrants rescatables: TOIIW) en Nasdaq e identifica a la empresa como una emerging growth company. El texto del 8-K no incluye tablas financieras detalladas ni resultados por partidas; para las cifras completas debe consultarse el Exhibit 99.1.
The Oncology Institute, Inc.는 2025년 6월 30일로 종료된 3개월에 대한 재무 실적 및 추가 재무 정보를 공개하는 보도자료를 제공했습니다. 제출 문서는 해당 보도자료가 Exhibit 99.1로 제공되었음을 명시하며, 이 정보가 Exchange Act에 따라 filed가 아닌 furnished로 제공되어 특정 법적 책임이 제한됨을 분명히 합니다. 보고서에는 나스닥에 등록된 회사의 증권(보통주: TOI; 환매 가능한 워런트: TOIIW)이 기재되어 있고, 회사를 emerging growth company로 규정하고 있습니다. 8-K 본문에는 상세한 재무표나 항목별 구체적 결과가 포함되어 있지 않으므로 전체 수치는 Exhibit 99.1을 참고해야 합니다.
The Oncology Institute, Inc. a publié un communiqué de presse qui dévoile ses résultats financiers et des informations financières supplémentaires pour les trois mois clos le 30 juin 2025. Le dépôt indique que le communiqué est fourni en tant qu'Exhibit 99.1 et précise que les informations sont furnished et non filed au titre de l'Exchange Act, limitant certaines responsabilités juridiques. Le rapport énumère les titres enregistrés de la société (actions ordinaires : TOI ; warrants remboursables : TOIIW) cotés au Nasdaq et identifie la société comme une emerging growth company. Le texte de l'8-K ne contient pas de tableaux financiers détaillés ni de résultats par poste ; pour les chiffres complets, il faut se référer à l'Exhibit 99.1.
The Oncology Institute, Inc. hat eine Pressemitteilung herausgegeben, die die Finanzergebnisse und ergänzende Finanzinformationen für die drei Monate zum 30. Juni 2025 offenlegt. Die Einreichung weist darauf hin, dass die Pressemitteilung als Exhibit 99.1 beigefügt ist und stellt klar, dass die Informationen im Sinne des Exchange Act furnished und nicht filed wurden, wodurch bestimmte rechtliche Haftungen eingeschränkt sind. Der Bericht listet die registrierten Wertpapiere des Unternehmens (Stammaktien: TOI; rückzahlbare Warrants: TOIIW) an der Nasdaq auf und kennzeichnet das Unternehmen als emerging growth company. Im 8-K-Text sind keine detaillierten Finanztabellen oder spezifischen Postenaufstellungen enthalten; die vollständigen Zahlen sind in Exhibit 99.1 nachzulesen.
FAQ
What did The Oncology Institute (TOIIW) disclose in this 8-K?
Is the information in this 8-K considered filed with the SEC?
Where can I find the detailed financial figures referenced in the 8-K?
Which securities of The Oncology Institute are registered and what are their tickers?
Does the 8-K indicate The Oncology Institute is an emerging growth company?
